HAEMOVIGILANCE IN SLOVENIA IN YEARS 2002–2006
Abstract
BACKGROUND Adverse reactions and preventive actions have accompanied transfusion medicine fromits beginning. Because of this, a haemovigilance system is imperative. The development ofthe haemovigilance system is taking place in Slovenia from 2000 ever since Law on BloodProcurement was adopted. METHODS The data of all adverse reactions was collected from 2002 in all hospitals where bloodtransfusions were being performed. Later, the collection of data of transfusion related unexpected red cell antibodies, near-miss events and of adverse reactions and events related tothe process begining with blood donation to the issuing of blood have begun. RESULTS From 2002 to 2006 there were 697 reports collected of nearly all types of adverse reactionsand events, with no report of any long-time morbidity or transfusion related deaths.46 reactions were severe. There were considerable differences among Slovenian hospitalsbetween the number of reports compared to the number of blood components issued,ranging from 1 to 3.5 adverse reactions per 1000 blood components issued. CONCLUSIONS The quality of adverse reactions and events reporting has been improving from 2002 to2006. The collected data represents the basis for the identification of critical points in theblood tranfusion chain as well as the improvement of blood transfusion safetyDownloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.